Operating Segments (Tables)

12 Months Ended

Dec. 31, 2022

Operating Segments

Schedule of operating segments

	For the Years Ended
	December 31,
	2022		2021
Revenues
Specialized BioTherapeutics	$	31,929	$	—
Public Health Solutions		916,982		824,268
Total	$	948,911	$	824,268
(Loss) Income from Operations
Specialized BioTherapeutics	$	(7,614,988)	$	(7,216,450)
Public Health Solutions		26,612		(542,270)
Corporate		(6,650,528)		(5,340,240)
Total	$	(14,238,904)	$	(13,098,960)
Amortization and Depreciation Expense
Specialized BioTherapeutics	$	10,087	$	7,804
Public Health Solutions		1,681		1,301
Corporate		12,794		25,056
Total	$	24,562	$	34,161
Other (Expense) Income, Net
Specialized BioTherapeutics	$	102,320	$	135,409
Corporate		(816,690)		(452,164)
Total	$	(714,370)	$	(316,755)
Share-Based Compensation
Specialized BioTherapeutics	$	138,075	$	136,594
Public Health Solutions		4,804		21,884
Corporate		190,510		203,081
Total	$	333,389	$	361,559

	As of December 31,
	2022		2021
Identifiable Assets
Specialized BioTherapeutics	$	103,742	$	128,645
Public Health Solutions		121,290		146,296
Corporate		14,054,685		26,594,986
Total	$	14,279,717	$	26,869,927